FAQ: Cybin Inc.'s $175M Registered Direct Offering and Corporate Overview
Summary
Cybin Inc. announced a $175 million registered direct offering of common shares and warrants priced at $6.51 per share, with participation from prominent healthcare and biotech investors. This significant capital raise supports the company's late-stage development of novel neuropsychiatry treatments for major depressive disorder and generalized anxiety disorder.
What is the main announcement from Cybin Inc.?
Cybin Inc. announced a registered direct offering of 22,277,750 common shares and pre-funded warrants priced at $6.51 per share, generating aggregate gross proceeds of approximately $175 million to fund the company’s operations and clinical development programs.
Who are the investors participating in this offering?
The offering includes participation from both new and existing investors such as Venrock Healthcare Capital Partners, OrbiMed, Point72, Deep Track Capital, Acorn Bioventures, Spruce Street Capital, Squadron Capital Management, Adage Capital Partners LP, Boxer Capital Management, ADAR1 Capital Management, Stonepine Capital Management, Pivotal Bioventure Partners and Ally Bridge Group.
What are the terms of the warrants included in this offering?
Each share or pre-funded warrant is accompanied by 0.35 of one common share purchase warrant exercisable at $8.14 per share until the earlier of June 30, 2027, 30 days after topline data is released for the APPROACH trial of CYB003 in major depressive disorder, or 30 days after an acceleration notice if the NYSE American closing price equals or exceeds $19.53 for five consecutive trading days.
What is Cybin Inc. and what does the company do?
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
What are Cybin’s key clinical development programs?
Cybin is currently developing CYB003, a proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder (with FDA Breakthrough Therapy Designation), and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder.
Where is Cybin operational?
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland, supporting its global clinical development and research activities.
Where can I find more detailed information about this offering?
To view the full press release, visit https://ibn.fm/TPxvo
Where can I find the latest news and updates about Cybin?
The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
Why is this capital raise significant for Cybin?
This $175 million capital raise provides substantial funding to advance Cybin’s late-stage clinical programs, particularly the Phase 3 development of CYB003 for major depressive disorder and Phase 2 development of CYB004 for generalized anxiety disorder, supporting the company’s mission to develop novel mental health treatments.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 267425